Pharming Group NV announced the results of its exploratory Phase II study on the safety and prophylactic effect of recombinant human C1 inhibitor ("rhC1INH") in patients with Hereditary Angioedema (HAE). The study is an open-label exploratory phase II study of the safety and prophylactic effect of more
To use all functions of this page, please activate cookies in your browser.
